TOVX Stock Overview
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
Notes are coming soon
Theriva Biologics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.07|
|52 Week High||US$4.39|
|52 Week Low||US$0.39|
|1 Month Change||84.48%|
|3 Month Change||46.46%|
|1 Year Change||-54.87%|
|3 Year Change||-81.31%|
|5 Year Change||-99.27%|
|Change since IPO||-99.82%|
Recent News & Updates
|TOVX||US Biotechs||US Market|
Return vs Industry: TOVX underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: TOVX underperformed the US Market which returned -9.6% over the past year.
|TOVX Average Weekly Movement||15.3%|
|Biotechs Industry Average Movement||12.1%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TOVX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: TOVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
Theriva Biologics, Inc. Fundamentals Summary
|TOVX fundamental statistics|
Is TOVX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TOVX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.30|
|Net Profit Margin||0.00%|
How did TOVX perform over the long term?See historical performance and comparison